IGFBP2 and breast carcinoma: Treatment with physiological concentrations of EGCG leads to growth inhibition in breast cancer cells mediated in part by ERα down-regulation, insulin-like growth factor binding protein-2 (IGFBP-2) reduction and p53/p21 upregulation [187].